The lactone or inner anhydrid of alpha-glycoheptonic acid (sold under the name of "hediosit"1) was introduced into the therapy of diabetes a few years ago by Prof. Georg Rosenfeld of Breslau, an investigator of carbohydrate metabolism. The features which seemed to recommend it, aside from its lack of toxicity and a very moderate degree of desired sweetness, were the alleged property of decreasing the glycosuria of the diabetic, along with some food value secured by the oxidation of the substance in the organism. The product appeared, therefore, to resemble glucose in its nutritive value, without exhibiting the lack of utilization experienced by the true sugars in diabetics. Hediosit has been fed in quantities of from 10 to 30 grams (3 drams to 1 ounce) per day without obvious untoward results, thus suggesting a means of supplying some energy in addition to antiglycosuric effects. Larger doses may lead to a
THE STATUS OF A THERAPEUTIC AGENT IN DIABETES. JAMA. 1915;LXIV(14):1165–1166. doi:10.1001/jama.1915.02570400047019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: